Zhixiang Jintai announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for the GR2302 injection product under development was approved. The indication is hepatitis B virus-related hepatocellular carcinoma.

Zhitongcaijing · 2d ago
Zhixiang Jintai announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, and the clinical trial application for the GR2302 injection product under development was approved. The indication is hepatitis B virus-related hepatocellular carcinoma.